CopenHeartSF—exploratory quantities subjected to post-hoc analysis
| Quantity | Time of measure | Type of quantity |
|---|---|---|
| Demographic | ||
| Age, height, weight | Baseline | Continuous |
| Marital, educational, occupational status | Baseline | Categorical |
| Smoking | Baseline | Binary (Y/N) |
| Clinical | ||
| Nutritional status (BMI) | Baseline | Continuous |
| NYHA classification | Baseline | Continuous |
| Type of heart disease | Baseline | Categorical |
| Type of sexual dysfunction | Baseline | Categorical |
| Diabetes mellitus | Baseline | Binary (Y/N) |
| Level of physical activity | Baseline | Categorical |
| Level of rehabilitation offered | Baseline | Categorical |
| PDE-5 inhibitor intake, Level of activity within the last 4 weeks, level of sexual activity | Baseline,W12, W16, M6 | Categorical |
| Para clinical | ||
| Cholesterol level | Baseline | Continuous |
| Functional capacity | ||
| Peak VO2 | Baseline, W12 | Continuous |
| Pelvic floor strength and endurance | Baseline, W12 | Continuous |
| Serious adverse events | W12, W16, M6 | Continuous |
| Questionnaires | ||
| SF-3668 HADS69 EQ-5D-5L70 FAME71 Sex after ICD questionnaire16 | Baseline,W16, M6 | Continuous |
BMI, body mass index; Eq-5D-5L, EuroQol; FAME, Female Assessment of Male Erectile Function; HADS, Hospital Anxiety and Depression Scale; NYHA, New York Heart Association; PDE-5, phosphodiesterase-5; SF-36, Short Form-36; Y/N, yes/no.